Premium
5‐Aza‐2′‐deoxycytidine and interleukin‐1 cooperate to regulate matrix metalloproteinase‐3 gene expression
Author(s) -
Couillard Julie,
Estève PierreOlivier,
Pradhan Sriharsa,
StPierre Yves
Publication year - 2011
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.25865
Subject(s) - epigenetics , dna methylation , methyltransferase , dnmt1 , gene expression , biology , enhancer , dnmt3b , transcription factor , regulation of gene expression , methylation , transcription (linguistics) , inflammation , microbiology and biotechnology , epigenetics of physical exercise , cancer research , promoter , gene , immunology , genetics , linguistics , philosophy
Members of the matrix metalloproteinase (MMP) family of enzymes play a critical role in extracellular matrix remodeling in a number of normal and pathologic processes. Accordingly, activation of MMP gene expression is tightly regulated at the level of transcription by specific transcription factors, most notably following exposure to inflammatory cytokines. Recent studies with 5‐aza‐2′‐deoxycytidine (5‐aza‐dC), a specific DNA methylase inhibitor, also suggest that epigenetic processes contribute to the regulation of MMP expression. Although inflammation‐related aberrant patterns of DNA methylation have been described, a mechanistic link between inflammation and epigenetic alterations in the control of MMP expression remains unclear. Here, we provide evidence that increased MMP‐3 expression by 5‐aza‐dC is modulated by interleukin‐1 (IL‐1). More specifically, we found that stimulation with IL‐1, but not with IL‐6 or TNFα, significantly increased the hypomethylation status of the MMP‐3 promoter to a level similar to that found in dnmt1/dnmt3b‐deficient HCT116 (DKO) cells. Furthermore, we showed that increased MMP‐3 expression by 5‐aza‐dC was associated with increased expression and activity of specific transcription factors known to regulate MMP‐3 expression. In fact, treatment with 5‐aza‐dC was obligatory for some transcription factors to trigger an increase in MMP‐3 expression, such as Ap‐1. In contrast, CCAAT enhancer‐binding proteins and E‐twenty six were capable of inducing MMP‐3 alone. Overall, these findings provide a novel perspective of the collaborative role of 5‐aza‐dC and inflammatory cytokines with specific transcription factors that are normally involved in MMP‐3 expression.